1 year ago
Overview of BCMA in Multiple Myeloma CAR-T Cell Therapy Introduction to BCMA BCMA (B-cell maturation antigen) is considered a major target for the treatment of multiple myeloma. Currently, the thre...
1 year ago
#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel Multiple myeloma Introduction: In recent years, there has been a breakthrough in the resea...
1 year ago
Ciltacabtagene Autoleucel(Carvykti) Approval Date Order The US Approval Time In February 2022, the US FDA officially approved Ciltacabtagene Autoleucel (brand name: CARVYKTI®, abbreviation: Cilta-c...
1 year ago
Ciltacabtagene Autoleucel(Carvykti) FDA Package Insert 1、Indications and Usage Carvykti (Ciltacabtagene Autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T...
1 year ago
Drug Resistance Mechanism and Clinical Significance of Bispecific T Cells and Multiple Myeloma Therapy Bispecific T Cell Engagers (TCEs) for Multiple Myeloma (MM) Bispecific T cell engagers (TCEs) ...
1 year ago
Multiple Myeloma and CAR-T,74% Reduced Risk of Multiple Myeloma Progression,BCMA-Targeted CAR-T Cell Therapy Advanced to Second-Line Treatment Advancement in Treatment Line – Ciltacabtagene A...
1 year ago
FDA Carvykti(Ciltacabtagene Autoleucel), Legend Biotech’s CAR-T Therapy, Advancing from Fourth-Line to Second-Line Treatment for Multiple Myeloma The long-awaited moment has finally arrived, ...
1 year ago
The ddBCMA CAR-T (Anitocabtagene Autoleucel, Anito-cel) with a Remarkable 100% ORR: The Dawn Finally Breaks for this CAR-T Therapy with a Turbulent Journey Preface On December 8, 2023, Arcellx rele...
1 year ago
ddBCMA CAR-T (now named Anitocabtagene Autoleucel, Anito-cel) Demonstrates Durable Efficacy with 100% Overall Response Rate At the end of 2023, Arcellx, an immune cell therapy company, revealed the...
1 year ago
Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward Liver cancer, CAR-T CT011 On January 15, 2024, #CARsgen Pharmaceuticals announced that its au...
1 year ago
Ciltacabtagene Autoleucel FDA Approved it for Second-line Treatment of Multiple Myeloma On April 5th, 2024 local time, Johnson & Johnson announced that the U.S. FDA has expanded the label for J...
1 year ago
🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈 cancer fight 🌟Mr. C from California, USA It’s yet another heartening piece of news as Mr. C from Cali...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
